Ramucirumab

Drug Profile

Ramucirumab

Alternative Names: Anti-flk-1 monoclonal antibody - ImClone; Anti-KDR monoclonal antibody - ImClone; Anti-VEGFR 2 monoclonal antibody - ImClone; Cyramza; IMC-1121; IMC-1121-B; IMC-1C11 - ImClone; LY-3009806

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Dyax
  • Developer AstraZeneca; Eli Lilly; Merck Sharp & Dohme; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma; Gastric cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer; Gastric cancer; Non-small cell lung cancer
  • Phase III Hepatocellular carcinoma; Oesophageal cancer; Urogenital cancer
  • Phase II Biliary cancer
  • Phase I Solid tumours
  • No development reported Breast cancer; Malignant melanoma; Ovarian cancer; Prostate cancer; Renal cell carcinoma

Most Recent Events

  • 02 Mar 2017 Phase-III clinical trials in Gastric cancer (Combination therapy, Second-line therapy or greater, Metastatic disease, Late-stage disease, Inoperable/Unresectable) in China (IV) (NCT02898077)
  • 02 Mar 2017 Phase-III clinical trials in Oesophageal cancer (Combination therapy, Second-line therapy or greater, Metastatic disease, Late-stage disease, Inoperable/Unresectable) in China (IV) (NCT02898077)
  • 02 Nov 2016 Eli Lilly and Company completes the phase III RAISE trial in Colorectal cancer (Second-line therapy or greater; Metastatic disease; Combination therapy) in USA, Argentina, Australia, Austria, Belgium, Brazil, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, South Korea, Netherlands, Portugal, Puerto Rico, Romania, Slovenia, Spain, Sweden and Taiwan (NCT01183780)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top